Personalized Medicine: Molecular Dx Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Personalized Medicine: Molecular Dx

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	6/6/2011 1:03:31 PM
	of 60

From Matt Herper’s blog ( blogs.forbes.com ): >> Clinical trials in cancer should soon involve genetic testing for all patients, moving to using DNA-sequencing technology like that made by Illumina as quickly as possible. The clinical trials groups are going to need to organize themselves to recruit patients for multiple studies at once, so that they won’t have to run through a hundred people or more just to get one who has the mutation they are testing. That will change the informed consent process, and the regulations that guide drug trials. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next